125 filings
Page 4 of 7
8-K
mw95qty16y1dvz1hv2
29 Apr 22
180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
6:44pm
8-K
hhlf0jtaq wy
28 Apr 22
Departure of Directors or Certain Officers
5:07pm
8-K
7tadl0j8ej
14 Apr 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:30pm
8-K
lirnzxhehw
28 Mar 22
Other Events
8:30am
8-K
dnyx6db
31 Jan 22
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
8:01am
8-K
1m7pwv9due flz30w
14 Dec 21
Submission of Matters to a Vote of Security Holders
8:31am
8-K
kt18i4
10 Dec 21
Departure of Directors or Certain Officers
8:17am
8-K
ujwhjsv8c37an 4tmb
6 Dec 21
180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results
8:15am
8-K
6rdzvr66t9 bf9vt
1 Dec 21
Regulation FD Disclosure
2:45pm
8-K
bwnx72fb
18 Nov 21
Regulation FD Disclosure
8:16am
8-K
wsf4dp
2 Nov 21
Departure of Directors or Certain Officers
8:30am
8-K
rhrj5j9df6fl17
5 Oct 21
Entry into a Material Definitive Agreement
8:16am
8-K
wwzofa4
20 Sep 21
Entry into a Material Definitive Agreement
4:30pm
8-K
zjvgy6wgdngauzjl8d3g
30 Aug 21
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders
7:30am
8-K
1zf25ctdqudz
27 Aug 21
Unregistered Sales of Equity Securities
4:30pm
8-K
roe4v1y75gc6
24 Aug 21
180 Life Sciences Corp. Announces $15.0 Million Private Placement
8:30am
8-K
0ibs8
10 Aug 21
Amendments to Articles of Incorporation or Bylaws
4:31pm
8-K
a4qqa8zdiin78q1jd3p9
6 Aug 21
Unregistered Sales of Equity Securities
4:23pm
8-K
8qgav9 8kmfi
2 Aug 21
Entry into a Material Definitive Agreement
4:45pm
8-K
s17f5uiyg17fxt8h
20 Jul 21
Other Events
8:31am